國立虎尾科技大學 |

Bone Regulators and Osteoporosis Therapy

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Bone Regulators and Osteoporosis Therapy/ edited by Paula H. Stern.
其他作者:	Stern, Paula H.
面頁冊數:	X, 518 p. 1 illus.online resource. :
Contained By:	Springer Nature eBook
標題:	Endocrinology. -
電子資源:	https://doi.org/10.1007/978-3-030-57378-2
ISBN:	9783030573782

Bone Regulators and Osteoporosis Therapy
Bone Regulators and Osteoporosis Therapy[electronic resource] /edited by Paula H. Stern. - 1st ed. 2020. - X, 518 p. 1 illus.online resource. - Handbook of Experimental Pharmacology,2620171-2004 ;. - Handbook of Experimental Pharmacology,224.

The cells of bone their interactions -- Parathyroid hormone and bone -- Vitamin D and bone -- Gonadal hormones and bone -- Thyroid hormones, glucocorticoids, insulin, and bone -- Growth factors and bone -- Prostaglandins and bone -- Cytokines and bone: osteoimmunology -- Chemokines and bone -- Calcium and bone -- FGF-23 and bone and mineral metabolism -- Nervous system mediators and bone -- Genetics of bone disorders -- Osteoporosis pathogenesis -- Structural and metabolic assessment of bone status -- Osteoporosis Therapeutics 2019 -- New targets and emergent therapies for osteoporosis -- Drugs causing bone loss -- Natural Products as potential bone therapies.

This volume is designed to provide an understanding of current and potential therapies for osteoporosis. The opening chapter introduces the cells of bone and their interactions. Several following chapters describe factors affecting bone including systemic hormones with significant effects on bone, and local mediators including growth factors, prostaglandins, cytokines and chemokines. Topics that have commanded particular attention recently are calcium, FGF-23, nervous system bone interactions. Drugs that cause bone loss provide important information on mechanism as well as therapeutic considerations. An overview of the genetics of bone disorders and a discussion of the pathophysiology of osteoporosis establish the clinical context. The final chapters discuss current and potential osteoporosis treatments. .

ISBN: 9783030573782

Standard No.: 10.1007/978-3-030-57378-2doiSubjects--Topical Terms:

645497
Endocrinology.

LC Class. No.: RM1-950

Dewey Class. No.: 615

Bone Regulators and Osteoporosis Therapy
LDR:02888nam a22004095i 4500 001 1029960
003 DE-He213
005 20201129012103.0
007 cr nn 008mamaa
008 210318s2020 gw | s |||| 0|eng d
020 $a 9783030573782 $9 978-3-030-57378-2
024 7 $a 10.1007/978-3-030-57378-2 $2 doi
035 $a 978-3-030-57378-2
050 4 $a RM1-950
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615 $2 23
245 1 0 $a Bone Regulators and Osteoporosis Therapy $h [electronic resource] / $c edited by Paula H. Stern.
250 $a 1st ed. 2020.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a X, 518 p. 1 illus. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Handbook of Experimental Pharmacology, $x 0171-2004 ; $v 262
505 0 $a The cells of bone their interactions -- Parathyroid hormone and bone -- Vitamin D and bone -- Gonadal hormones and bone -- Thyroid hormones, glucocorticoids, insulin, and bone -- Growth factors and bone -- Prostaglandins and bone -- Cytokines and bone: osteoimmunology -- Chemokines and bone -- Calcium and bone -- FGF-23 and bone and mineral metabolism -- Nervous system mediators and bone -- Genetics of bone disorders -- Osteoporosis pathogenesis -- Structural and metabolic assessment of bone status -- Osteoporosis Therapeutics 2019 -- New targets and emergent therapies for osteoporosis -- Drugs causing bone loss -- Natural Products as potential bone therapies.
520 $a This volume is designed to provide an understanding of current and potential therapies for osteoporosis. The opening chapter introduces the cells of bone and their interactions. Several following chapters describe factors affecting bone including systemic hormones with significant effects on bone, and local mediators including growth factors, prostaglandins, cytokines and chemokines. Topics that have commanded particular attention recently are calcium, FGF-23, nervous system bone interactions. Drugs that cause bone loss provide important information on mechanism as well as therapeutic considerations. An overview of the genetics of bone disorders and a discussion of the pathophysiology of osteoporosis establish the clinical context. The final chapters discuss current and potential osteoporosis treatments. .
650 2 4 $a Endocrinology. $3 645497
650 2 4 $a Receptors. $3 787639
650 2 4 $a Metabolic Diseases. $3 593967
650 2 4 $a Cytokines and Growth Factors. $3 787581
650 2 4 $a Cell Physiology. $3 591630
650 1 4 $a Pharmacology/Toxicology. $3 593882
650 0 $a Endocrinology . $3 1254221
650 0 $a Proteins . $3 1253493
650 0 $a Metabolic diseases. $3 1253620
650 0 $a Growth factors. $3 872208
650 0 $a Cytokines. $3 581465
650 0 $a Cell physiology. $3 674413
650 0 $a Pharmacology. $3 583819
700 1 $a Stern, Paula H. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1326778
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030573775
776 0 8 $i Printed edition: $z 9783030573799
776 0 8 $i Printed edition: $z 9783030573805
830 0 $a Handbook of Experimental Pharmacology, $x 0171-2004 ; $v 224 $3 1254015
856 4 0 $u https://doi.org/10.1007/978-3-030-57378-2
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)